Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirabegron for cardiac structural remodeling and diastolic dysfunction
2015-003146-75Phase 2Completed
- Sponsor
- UCLouvain
- Start
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in Structural Cardiac Abnormality, heart failure with preserved ejection fraction (HFpEF) and heart failure (HF) comparing Mirabegron with Placebo (2 arms). Primary endpoints: Change in left ventricular mass and Change in diastolic function. Started Mar 2016; status: completed.
02
Drugs
mirabegron
03
Conditions
Structural Cardiac Abnormalityheart failure with preserved ejection fraction (HFpEF)heart failure (HF)
Beyond the preview
Go deeper on 2015-003146-75.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003146-75.